Masters Capital Management’s bluebird bio BLUE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-48,750
Closed -$407K 71
2024
Q4
$407K Hold
48,750
0.02% 75
2024
Q3
$507K Hold
48,750
0.02% 63
2024
Q2
$960K Sell
48,750
-1,250
-3% -$25K 0.05% 63
2024
Q1
$1.28M Hold
50,000
0.05% 66
2023
Q4
$1.38M Buy
+50,000
New +$3.05M 0.06% 58
2018
Q4
Sell
-16,241
Closed -$30.7M 55
2018
Q3
$30.7M Sell
16,241
-5,978
-27% -$12.3M 0.76% 38
2018
Q2
$45.2M Buy
22,219
+6,779
+44% +$15.5M 1.27% 21
2018
Q1
$34.1M Buy
15,440
+5,790
+60% +$14.7M 0.74% 31
2017
Q4
$22.3M Buy
+9,650
New +$19.6M 0.53% 44

Other funds holding BLUE

Masters Capital Management's BLUE Position: Q1 2025 in Review

Masters Capital Management sold out of bluebird bio (BLUE) in Q1 2025, closing a stake of 48,750 shares — an estimated $407K sold.

Masters Capital Management first reported a position in BLUE in Q4 2017 and held it in 9 quarters. The position peaked at $45.2M in Q2 2018. 85 funds tracked by Wall St. Rank hold BLUE as of Q1 2025.

  • Masters Capital Management reported no remaining bluebird bio position as of Q1 2025 after selling out during the quarter.
  • Masters Capital Management sold 48,750 bluebird bio shares in Q1 2025, an estimated $407K.
  • Masters Capital Management first reported a position in bluebird bio in Q4 2017 and held it in 9 quarters.
  • Masters Capital Management's bluebird bio position peaked at $45.2M in Q2 2018.
  • 85 funds tracked by Wall St. Rank held bluebird bio as of Q1 2025.

Based on Masters Capital Management's 13F filing for Q1 2025, filed 15 May 2025.